This article is more than 5 years old. Information may no longer be current.

Sight Sciences' Omni Surgical System cleared by FDA

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has cleared the Omni Surgical System, according to a press release from Sight Sciences.

The Omni system is indicated for the delivery of controlled volumes of viscoelastic fluid in the anterior segment including Schlemm’s canal and the cutting of trabecular meshwork tissue.

“This is a major milestone for Sight Sciences and further expands our portfolio of solutions for ophthalmologists performing angle surgery,” Shawn O’Neil Sr., vice president of sales and marketing for the company, said in the release.

In addition, Sight Sciences announced three new hires: Patrick Smale will serve as vice president of marketing for surgical glaucoma; Jeff Francis will serve as vice president of sales for surgical glaucoma; and Todd Love will serve as vice president of marketing for dry eye.

“Our core commercial leadership team now holds more than 70 years of collective experience in commercial excellence in the ophthalmology and optometry spaces and is poised to lead Sight Sciences’ strategic objectives,” CEO Paul Badawi said in the release.